Adjuvia Therapeutics is a privately held biotech company with the goal of developing novel therapeutics to address chronic diseases that arise from mitochondrial and cellular dysfunction. Adjuvia’s lead compound, ATI-103, is a proprietary formulation of astaxanthin, a powerful antioxidant that protects cells from damage that occurs during mitochondrial energy production, and regulates many cell signaling pathways important for immune function and metabolic homeostasis. Dysregulation and inherited genetic mutations in the mitochondria can can lead to unmitigated oxidative stress, resulting in cell death, organ dysfunction and chronic disease. For more information please visit www.adjuviatx.com